Clinical Trials Logo

Clinical Trial Details — Status: Available

Administrative data

NCT number NCT04566393
Other study ID # ULI-EAP-100
Secondary ID
Status Available
Phase
First received
Last updated

Study information

Verified date August 2023
Source xCures
Contact xCures Clinical Operations
Phone (707) 641-4475
Email expandedaccess@xcures.com
Is FDA regulated No
Health authority
Study type Expanded Access

Clinical Trial Summary

The objective of this expanded access program is to provide ulixertinib (BVD-523) for compassionate use in advanced cancer patients with MAPK pathway-altered solid tumor(s), including but not limited to KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations who have incomplete response to or have exhausted available therapies. Ulixertinib is available for treatment as monotherapy or in combination with other clinically tolerable agent(s), conditionally approved by the drug manufacturer.


Recruitment information / eligibility

Status Available
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers
Gender All
Age group 12 Years and older
Eligibility Inclusion Criteria: - Main Inclusion Criterion: 1. Patient has a MAPK pathway-altered solid tumor(s), including but not limited to KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations. - Other Inclusion Criteria: 1. In the opinion of the treating physician, the patient has exhausted or has inadequate response to available anti-cancer treatments. 2. In the opinion of the treating physician, the patient has adequate organ function to tolerate ulixertinib as defined in section 6.1 3. Male or female patients aged = 12 years. 4. Patient must be able to swallow and retain orally administered medication. Note: Ulixertinib is primarily absorbed in the duodenum and therefore patients with any prior stomach or duodenal resection should be evaluated with that understanding. 5. For females, evidence of post-menopausal status or negative urinary or serum pregnancy test for pre-menopausal patients. 6. Highly effective contraception for both male and female patients throughout the treatment and for at least 4 months after last treatment administration. In patients under the age of 18, who are not sexually active, abstinence is an acceptable form. 7. Toxicities related to any prior treatments are either stable, stable on supportive therapy, resolved, or in the opinion of the treating physician, clinically non-significant 8. Ability to understand a written informed consent document, and the willingness to sign it. Assent will be obtained when appropriate based on the patient's age. Exclusion Criteria: 1. Patient is already participating in or qualifies for and is able to enroll in a clinical trial of ulixertinib (BVD-523). 2. Patient has received systemic therapy with an investigational agent within 5 half-lives or 14 days prior to starting ulixertinib treatment, whichever is shorter. 3. Patient has received radiotherapy within 14 days prior to the first dose of ulixertinib treatment other than for the allowable treatment of symptomatic bone metastasis. 4. A history of current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR) 5. Current evidence of uncontrolled, significant intercurrent illness that would, in the treating physician's judgment, contraindicate the patient's treatment with ulixertinib due to safety concerns. 6. Patients who, in the opinion of the treating physician, have not fully recovered from recent major surgery to a sufficient extent to tolerate treatment with ulixertinib. 7. Known hypersensitivity to ulixertinib or any component in its formulation. 8. Patients taking prohibited medications as described in current Investigator's Brochure. Note: Patients who require treatment with Drugs that are strong inhibitors or inducers of CYP1A2, CYP2D6, and CYP3A4 (see Appendix 3) were excluded from the FIH study of ulixertinib and should be discussed with xCures to review if any potential benefits outweigh the potential risks. 9. Patient is actively breastfeeding. 10. Prior stomach or duodenal resection that in the opinion of the treating physician would affect the breakdown and absorption of ulixertinib.

Study Design


Related Conditions & MeSH terms

  • Bladder Cancer
  • BRAF Gene Mutation
  • Cholangiocarcinoma
  • Colorectal Cancer
  • ERK Mutation
  • Esophageal Cancer
  • Gastric Cancer
  • Glioblastoma
  • Head and Neck Cancer
  • Hepatocellular Carcinoma
  • HRAS Gene Mutation
  • KRAS Activating Mutation
  • MAPK Gene Mutation
  • MEK Mutation
  • Melanoma
  • Non Small Cell Lung Cancer
  • NRAS Gene Mutation
  • Ovarian Cancer
  • Pancreatic Cancer
  • Small Bowel Cancer
  • Thyroid Cancer

Intervention

Drug:
Ulixertinib (BVD-523)
Ulixertinib (BVD-523) is an oral, first-in-class ERK1/2 inhibitor

Locations

Country Name City State
United States Lehigh Valley Health Network Allentown Pennsylvania
United States PCR Oncology Arroyo Grande California
United States Mount Desert Island Hospital Bar Harbor Maine
United States Mary Bird Perkins Cancer Center Baton Rouge Louisiana
United States University of Alabama at Birmingham Birmingham Alabama
United States The Christ Hospital Cincinnati Ohio
United States Iowa Oncology Research Association Des Moines Iowa
United States Clearview Cancer Institute Huntsville Alabama
United States Cancer Partners of Nebraska Lincoln Nebraska
United States Monmouth Medical Center Long Branch New Jersey
United States Kaiser Permanente Los Angeles Medical Center Los Angeles California
United States The Minniti Center for Medical Oncology and Hematology Mickleton New Jersey
United States Infirmary Cancer Care Mobile Alabama
United States Hoag Memorial Hospital Presbyterian Newport Beach California
United States Orlando Health Orlando Florida
United States xCures Inc. San Francisco California
United States Providence Saint John's Health Center Santa Monica California
United States Seattle Cancer Care Alliance Seattle Washington
United States Oakland Macomb Cancer Specialists Sterling Heights Michigan
United States Stony Brook Cancer Center Stony Brook New York
United States Atlantic Health System/Overlook Medical Center Summit New Jersey
United States The Toledo Clinic Cancer Center Toledo Ohio
United States MedStar Georgetown University Hospital Washington District of Columbia

Sponsors (2)

Lead Sponsor Collaborator
xCures Cancer Commons

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A